Department of Obstetrics & Gynecology, University of Washington, Box 356460, Seattle, WA 98195-6460, USA.
Hum Reprod. 2012 Sep;27(9):2607-12. doi: 10.1093/humrep/des244. Epub 2012 Jun 29.
Fetal cells (microchimerism) are acquired by women during pregnancy. Fetal microchimerism persists decades later and includes cells with pluripotent capacity. Persistent microchimerism has the capacity for both beneficial and detrimental maternal health consequences. Both miscarriage and termination of pregnancy can result in fetal microchimerism. We sought to determine whether cellular fetal microchimerism is acquired during management of pregnancy loss and further explored factors that could influence fetal cell transfer, including viability of fetal tissue, surgical versus medical management and gestational age.
Pregnant women (n= 150 samples from 75 women) with singleton pregnancies undergoing a TOP (n= 63) or treatment for embryonic or fetal demise (miscarriage, n= 12) were enrolled. Mononuclear cells were isolated from blood samples drawn before, and 30 min after, treatment. Fetal cellular microchimerism concentrations were determined using quantitative PCR for a Y chromosome-specific sequence, expressed as genome equivalents of fetal DNA per 100 000 maternal cell equivalents (gEq/10(5)). Detection rate ratios were determined according to clinical characteristics.
Cellular fetal microchimerism was found more often in post- compared with pretreatment samples, 24 versus 5% (P= 0.004) and at higher concentrations, 0-36 versus 0-0.7 gEq/10(5) (P< 0.001). Likelihood of microchimerism was higher in surgical than medical management, detection rate ratio 24.7 (P= 0.02). The detection rate ratio for TOP versus miscarriage was 16.7 for known male fetuses (P= 0.02). Microchimerism did not vary with gestational age.
Significant fetal cell transfer occurs during miscarriage and TOP. Exploratory analyses support relationships between obstetric clinical factors and acquisition of fetal cellular microchimerism; however, our limited sample size precludes definitive analysis of these relationships, and confirmation is needed. In addition, the long-term persistence and potential consequences of fetal microchimerism on maternal health merit further investigation.
胎儿细胞(微嵌合体)在女性怀孕期间被获得。胎儿微嵌合体在几十年后仍然存在,包括具有多能性的细胞。持续的微嵌合体既有对母亲健康有益的后果,也有有害的后果。流产和终止妊娠都可能导致胎儿微嵌合体。我们试图确定在妊娠丢失的管理过程中是否获得了细胞性胎儿微嵌合体,并进一步探讨了可能影响胎儿细胞转移的因素,包括胎儿组织的活力、手术与药物管理以及孕龄。
患有单胎妊娠的孕妇(75 名妇女的 150 个样本),接受了终止妊娠(n=63)或胚胎或胎儿死亡(流产,n=12)的治疗。从治疗前和治疗后 30 分钟采集的血液样本中分离出单核细胞。使用针对 Y 染色体特异性序列的定量 PCR 确定胎儿细胞微嵌合体浓度,以每 100000 个母体细胞当量(gEq/105)的胎儿 DNA 基因组当量表示(gEq/105)。根据临床特征确定检测率比值。
与治疗前相比,治疗后样本中更常发现细胞性胎儿微嵌合体,分别为 24%和 5%(P=0.004),浓度更高,分别为 0-36 和 0-0.7 gEq/105(P<0.001)。手术管理比药物管理更有可能发生微嵌合体,检测率比值为 24.7(P=0.02)。对于已知男性胎儿,终止妊娠与流产的检测率比值为 16.7(P=0.02)。微嵌合体与孕龄无关。
在流产和终止妊娠期间会发生显著的胎儿细胞转移。探索性分析支持产科临床因素与胎儿细胞微嵌合体获得之间的关系;然而,我们的样本量有限,无法对这些关系进行明确分析,需要进一步确认。此外,胎儿微嵌合体对母亲健康的长期持续存在和潜在影响值得进一步研究。